Clinical Trial Update: Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated whether Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) alters the pharmacokinetics of rosuvastatin in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Deutivacaftor (Deutivacaftor)
• Rosuvastatin (rosuvastatin)
• Tezacaftor (Tezacaftor)
• Vanzacaftor (Vanzacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED